-
Je něco špatně v tomto záznamu ?
Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate
L. Sivak, V. Subr, J. Tomala, B. Rihova, J. Strohalm, T. Etrych, M. Kovar,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- chemorezistence MeSH
- cytostatické látky aplikace a dávkování MeSH
- doxorubicin aplikace a dávkování MeSH
- experimentální nádory farmakoterapie patologie MeSH
- inbrední kmeny myší MeSH
- methakryláty chemie MeSH
- mnohočetná léková rezistence MeSH
- myši nahé MeSH
- myši MeSH
- nádorové buněčné linie MeSH
- nanokapsle aplikace a dávkování chemie MeSH
- nanokonjugáty aplikace a dávkování chemie MeSH
- oligopeptidy aplikace a dávkování MeSH
- P-glykoprotein antagonisté a inhibitory MeSH
- protokoly antitumorózní kombinované chemoterapie aplikace a dávkování MeSH
- výsledek terapie MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Multidrug resistance (MDR) is a common cause of failure in chemotherapy for malignant diseases. MDR is either acquired as a result of previous repeated exposure to cytostatic drugs (P388/MDR cells) or naturally, as some tumors are congenitally resistant to chemotherapy (CT26 cells). One of the most common mechanisms of MDR is upregulation of P-glycoprotein (P-gp) expression. Here, we used HPMA copolymer conjugates, whereby the cytostatic drug doxorubicin (Dox) or the derivative of the P-gp inhibitor reversin 121 (R121) or both were covalently bound through a degradable pH-sensitive hydrazone bond. We proved that R121, when bound to a polymeric carrier, is capable of inhibiting P-gp in P388/MDR cells and sensitizing them in relation to the cytostatic activity of Dox. Conjugate bearing both Dox and R121 was found to be far more potent in P388/MDR cells than conjugate bearing Dox alone or a mixture of conjugates bearing either Dox or R121 when cytostatic activity in vitro, cell cycle arrest, accumulation of Dox in cells and induction of apoptosis were determined. Importantly, conjugate bearing R121 is also effective in vivo as it inhibits P-gp in P388/MDR tumors after intraperitoneal administration, while both the conjugate bearing Dox and R121 induces apoptosis in P388/MDR tumors more effectively than conjugate bearing Dox alone. Only conjugate bearing Dox and R121 significantly inhibited P388/MDR tumor growth and led to the prolonged survival of treated mice. However, the most dramatic antitumor activity of this conjugate was found in the CT26 tumor model where it completely cured six out of eight experimental mice, while conjugate bearing Dox alone cured no mice.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18016896
- 003
- CZ-PrNML
- 005
- 20180523093311.0
- 007
- ta
- 008
- 180515s2017 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.biomaterials.2016.11.013 $2 doi
- 035 __
- $a (PubMed)27886555
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Sivak, Ladislav $u Institute of Microbiology of the Czech Academy of Sciences, v.v.i., Videnska 1083, 14220 Prague, Czechia.
- 245 10
- $a Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate / $c L. Sivak, V. Subr, J. Tomala, B. Rihova, J. Strohalm, T. Etrych, M. Kovar,
- 520 9_
- $a Multidrug resistance (MDR) is a common cause of failure in chemotherapy for malignant diseases. MDR is either acquired as a result of previous repeated exposure to cytostatic drugs (P388/MDR cells) or naturally, as some tumors are congenitally resistant to chemotherapy (CT26 cells). One of the most common mechanisms of MDR is upregulation of P-glycoprotein (P-gp) expression. Here, we used HPMA copolymer conjugates, whereby the cytostatic drug doxorubicin (Dox) or the derivative of the P-gp inhibitor reversin 121 (R121) or both were covalently bound through a degradable pH-sensitive hydrazone bond. We proved that R121, when bound to a polymeric carrier, is capable of inhibiting P-gp in P388/MDR cells and sensitizing them in relation to the cytostatic activity of Dox. Conjugate bearing both Dox and R121 was found to be far more potent in P388/MDR cells than conjugate bearing Dox alone or a mixture of conjugates bearing either Dox or R121 when cytostatic activity in vitro, cell cycle arrest, accumulation of Dox in cells and induction of apoptosis were determined. Importantly, conjugate bearing R121 is also effective in vivo as it inhibits P-gp in P388/MDR tumors after intraperitoneal administration, while both the conjugate bearing Dox and R121 induces apoptosis in P388/MDR tumors more effectively than conjugate bearing Dox alone. Only conjugate bearing Dox and R121 significantly inhibited P388/MDR tumor growth and led to the prolonged survival of treated mice. However, the most dramatic antitumor activity of this conjugate was found in the CT26 tumor model where it completely cured six out of eight experimental mice, while conjugate bearing Dox alone cured no mice.
- 650 _2
- $a P-glykoprotein $x antagonisté a inhibitory $7 D020168
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protokoly antitumorózní kombinované chemoterapie $x aplikace a dávkování $7 D000971
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a cytostatické látky $x aplikace a dávkování $7 D054697
- 650 _2
- $a doxorubicin $x aplikace a dávkování $7 D004317
- 650 _2
- $a mnohočetná léková rezistence $7 D018432
- 650 _2
- $a chemorezistence $7 D019008
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a methakryláty $x chemie $7 D008689
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a inbrední kmeny myší $7 D008815
- 650 _2
- $a myši nahé $7 D008819
- 650 _2
- $a nanokapsle $x aplikace a dávkování $x chemie $7 D053769
- 650 _2
- $a nanokonjugáty $x aplikace a dávkování $x chemie $7 D058726
- 650 _2
- $a experimentální nádory $x farmakoterapie $x patologie $7 D009374
- 650 _2
- $a oligopeptidy $x aplikace a dávkování $7 D009842
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Subr, Vladimir $u Institute of Macromolecular Chemistry of the Czech Academy of Sciences, v.v.i., Heyrovskeho nam. 2, 16206 Prague, Czechia.
- 700 1_
- $a Tomala, Jakub $u Institute of Microbiology of the Czech Academy of Sciences, v.v.i., Videnska 1083, 14220 Prague, Czechia.
- 700 1_
- $a Rihova, Blanka $u Institute of Microbiology of the Czech Academy of Sciences, v.v.i., Videnska 1083, 14220 Prague, Czechia.
- 700 1_
- $a Strohalm, Jiri $u Institute of Macromolecular Chemistry of the Czech Academy of Sciences, v.v.i., Heyrovskeho nam. 2, 16206 Prague, Czechia.
- 700 1_
- $a Etrych, Tomas $u Institute of Macromolecular Chemistry of the Czech Academy of Sciences, v.v.i., Heyrovskeho nam. 2, 16206 Prague, Czechia.
- 700 1_
- $a Kovar, Marek $u Institute of Microbiology of the Czech Academy of Sciences, v.v.i., Videnska 1083, 14220 Prague, Czechia. Electronic address: makovar@biomed.cas.cz.
- 773 0_
- $w MED00000753 $t Biomaterials $x 1878-5905 $g Roč. 115, č. - (2017), s. 65-80
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27886555 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180523093456 $b ABA008
- 999 __
- $a ok $b bmc $g 1300520 $s 1013736
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 115 $c - $d 65-80 $e 20161112 $i 1878-5905 $m Biomaterials $n Biomaterials $x MED00000753
- LZP __
- $a Pubmed-20180515